A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

Gene Therapy

Volumn 16, Issue 3, 2009, Pages 376-382

  Li, J L ^a   Liu, H L ^b,c   Zhang, X R ^a   Xu, J P ^a   Hu, W K ^b   Liang, M ^b   Chen, S Y ^d   Hu, F ^b   Chu, D T ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b Shanghai Sunway Biotech Co Ltd   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HEAT SHOCK PROTEIN 70; ONCOLYTIC ADENOVIRUS;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GENE OVEREXPRESSION; HUMAN; INJECTION SITE REACTION; IRON DEFICIENCY ANEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LUNG CANCER; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MELANOMA; NATURAL KILLER CELL; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR REGRESSION;

ADENOVIRIDAE; ADULT; AGED; ANTIBODIES, NEOPLASM; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INJECTIONS, INTRALESIONAL; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALIA; MACACA MULATTA; MUS;

EID: 62549085594     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.179     Document Type: Article

References (38)

1. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-375.
2. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R et al Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806.
3. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-623.
4. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006; 98: 298-300.
5. David HK. The end of the beginning: Oncolytic virotherapy achieves clinical proof-of-concept. Mol Ther 2006; 13: 237-238.
6. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007; 7: 659-670.
7. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 2004; 23: 1666-1670.
8. Nover L, Scharf KD. Heat shock proteins. In: Nover L (ed). Heat Shock Response. CRC Press: Boca Raton, FL, 1991, pp 41-128.
9. Georgopoulos C, Welch WJ. Role of the major heat shock proteins as molecular chaperones. Annu Rev Cell Biol 1993; 9: 601-634.
10. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278: 117-120.
11. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20: 395-425.
12. Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 2002; 158: 1277-1285.
13. Binder RJ, Han DK, Srivastava PK. CD91: A receptor for heat shock protein gp96. Nat Immunol 2000; 1: 151-155.
14. Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem 2001; 276: 17163-17171.
15. Hunt S. Technology evaluation: HspE7, StressGen Biotechnologies Corp. Curr Opin Mol Ther 2001; 3: 413-417.
16. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived Hsp gp96 preparations: A pilot study. Int J Cancer 2000; 88: 232-238.
17. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L et al Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. J Clin Oncol 2008; 26: 955-962.
18. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial. Lancet 2008; 372: 145-154.
19. Huang XF, Ren W, Rollins L, Pittman P, Shah M, Shen L et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res 2003; 63: 7321-7329.
20. Neckers L. Heat shock protein 90: The cancer chaperone. J Biosci 2007; 32: 517-530.
21. Queitsch C, Sangster TA, Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature 2002; 417: 618-624.
22. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003; 14: 1169-1176.
23. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005; 8: 61-74.
24. Chuah MK, Collen D, VandenDriessche T. Biosafety of adenoviral vectors. Curr Gene Ther 2003; 3: 527-543.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
26. Thorne SH, Brooks G, Lee YL, Au T, Eng LF, Reid T. Effects of febrile temperature on adenoviral infection and replication: Implications for viral therapy of cancer. J Virol 2005; 79: 581-591.
27. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005; 8: 61-74.
28. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-566.
29. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561.
30. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003; 9: 693-702.
31. Xu RH, Yuan ZY, Guan ZZ, Cao Y, Wang HQ, Hu XH et al. Phase II clinical study of intratumoral H101, an EI B deleted adenovirus, in patients with cancer. China Oncol 2004; 14: 12-18.
32. McShine RL, Sibinga S, Brozovic B. Differences between the effects of EDTA and citrate anticoagulants on platelet count and mean platelet volume. Clin Lab Haematol 1990; 12: 277-285.
33. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007; 25: 243-265.
34. Novellino L, Castelli C, Parmiani GA. Listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54: 187-207.
35. Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 1988; 110: 29-36.
36. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94-96.
37. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995; 14: 1149-1161.
38. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.